{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=8", "query": { "intervention": "Phase 1b", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 2479, "total_pages": 248, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Phase+1b&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T10:18:38.125Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03310957", "title": "Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "ladiratuzumab vedotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "2018-02-27", "completion_date": "2024-09-30", "has_results": true, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-10-19T10:18:38.125Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03310957" }, { "nct_id": "NCT05933265", "title": "Study of LP-184 in Patients With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Solid Tumor", "GBM", "TNBC - Triple-Negative Breast Cancer", "NSCLC", "Pancreatic Adenocarcinoma", "DDR Gene Mutation" ], "interventions": [ { "name": "LP-184", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Nivolumab & Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lantern Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2023-06-09", "completion_date": "2026-07-28", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-19T10:18:38.125Z", "location_count": 7, "location_summary": "Springdale, Arkansas • Indianapolis, Indiana • Louisville, Kentucky + 4 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05933265" }, { "nct_id": "NCT06633757", "title": "Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Primary Ciliary Dyskinesia (PCD)" ], "interventions": [ { "name": "RCT1100", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ReCode Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 14, "start_date": "2024-10-22", "completion_date": "2026-02-10", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-19T10:18:38.125Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06633757" }, { "nct_id": "NCT01998971", "title": "A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Daratumumab", "type": "DRUG" }, { "name": "Velcade", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Thalidomide", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2014-02-18", "completion_date": "2024-01-11", "has_results": false, "last_update_posted_date": "2025-04-25", "last_synced_at": "2026-10-19T10:18:38.125Z", "location_count": 10, "location_summary": "Duarte, California • Atlanta, Georgia • Chicago, Illinois + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01998971" }, { "nct_id": "NCT01455532", "title": "A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Malignant" ], "interventions": [ { "name": "Iniparib (SAR240550-BSI-201)", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Placlitaxel", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2011-11", "completion_date": "2014-04", "has_results": false, "last_update_posted_date": "2014-10-22", "last_synced_at": "2026-10-19T10:18:38.125Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Augusta, Georgia + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01455532" }, { "nct_id": "NCT06885281", "title": "A Study of ZL-1310 in Participants With Selected Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "ZL-1310", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zai Lab (Shanghai) Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 166, "start_date": "2025-05-12", "completion_date": "2028-04", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-19T10:18:38.125Z", "location_count": 12, "location_summary": "San Francisco, California • Peoria, Illinois • Detroit, Michigan + 9 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06885281" }, { "nct_id": "NCT07408232", "title": "A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Retinitis Pigmentosa" ], "interventions": [ { "name": "Phase 1b/2: Cohort 1 - OCT-980 Tablet", "type": "DRUG" }, { "name": "Phase 1b/2: Cohort 2 - OCT-980 Tablet", "type": "DRUG" }, { "name": "Phase 1b/2: Cohort 3 - OCT-980 Tablet", "type": "DRUG" }, { "name": "Phase 1b/2: Cohort 4 - OCT-980 Tablet", "type": "DRUG" }, { "name": "Phase 1b/2: Cohort 5 - OCT-980 Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Octant, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2026-03-10", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-19T10:18:38.125Z", "location_count": 2, "location_summary": "Portland, Oregon • Dallas, Texas", "locations": [ { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07408232" }, { "nct_id": "NCT04882163", "title": "Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma, B-Cell" ], "interventions": [ { "name": "CC-220", "type": "DRUG" }, { "name": "Polatuzumab vedotin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-10-10", "completion_date": "2029-04-07", "has_results": false, "last_update_posted_date": "2021-10-05", "last_synced_at": "2026-10-19T10:18:38.125Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Ann Arbor, Michigan • Sioux Falls, South Dakota", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04882163" }, { "nct_id": "NCT07734064", "title": "A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stargardt Disease", "Stargardt Macular Dystrophy", "Stargardt-like Macular Dystrophy" ], "interventions": [ { "name": "ASP2020", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Institute for Regenerative Medicine", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 30, "start_date": "2026-08-10", "completion_date": "2029-09-30", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-19T10:18:38.125Z", "location_count": 3, "location_summary": "Phoenix, Arizona • Cincinnati, Ohio • Dallas, Texas", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07734064" }, { "nct_id": "NCT07145177", "title": "177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Prostate Cancer", "Prostate Cancer" ], "interventions": [ { "name": "177Lu-PSMA-617", "type": "DRUG" }, { "name": "Ablation", "type": "PROCEDURE" }, { "name": "Trans-arterial chemoembolization (TACE)", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography (PET)/Computerized tomography (CT)", "type": "PROCEDURE" }, { "name": "Tumor Biopsy", "type": "PROCEDURE" }, { "name": "Questionnaire", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 30, "start_date": "2026-03-16", "completion_date": "2030-10-31", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-19T10:18:38.125Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07145177" } ] }